From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q2 2017 call → NO我们根据提供的文本内容来判断。管理层是否描述了公司最近从需要说服的候选者转变为已批准、指定、列入、合格、注册、报销或预先授权的选择,进入买方的采购、报销、处方集、规格、采购、网络、目录或计划系统,从而使得未来业务的一部分可以在没有每次单独销售事件的情况下到来,并且管理层是否传达了这种准入状态是新的,以至于它解锁的大部分量仍在前方。 在文本中,关于SPINRAZA的讨论:管理层提到在美国有超过80%的商业保险覆盖人群有政策,约三分之二有广泛准入;Medicaid约三分之二的覆盖人群有正式政策,60%有广泛准入。这描述了进入保险覆盖和报销系统。但这是否是“最近”的?管理层说“我们继续看到在覆盖和报销方面取得强劲进展”,并且提到“在Q2,大约20%的单位作为免费药物分发,而Q1为25%”,这表明覆盖改善导致免费药物使用减少。但管理层是否明确说这种准入是新的,并且大部分量还在前方?管理层说“我们相信SPINRAZA将成为我们最大的商业资产之一”,但并没有明确说这种准入状态是新的,且大部分量尚未实现。此外,关于新生儿筛查,提到SMA被接受进入审查过程,但这是未来可能。关于欧洲、日本、加拿大等地的批准,但那是监管批准,不是准入系统。 关于MS的价值型合同,管理层提到执行了四个协议,但那是试点,不是广泛准入。 因此,没有明确描述公司已进入一个系统,使得未来业务无需单独销售事件即可到来,并且这种状态是新的且大部分量在前方。所以答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.